AlloVir reports FY2022 net loss of $168.7M and positive Phase 2 posoleucel data in kidney transplant

Kalaris Therapeutics, Inc.

2022-FY EPS reported -$2.20

FY2022 net loss $168.7M ($2.20/share); R&D spend $118.9M; cash & securities $233.8M as of Dec 31, 2022.
2023 operating expense guidance of $150-170M (excl. non-cash); Phase 3 enrollment completion expected by end of 2023 with 2024 data.
Phase 2 study: posoleucel achieved ≥1-log viral load reduction in 39% vs 14% placebo; biweekly dosing 50%.
In high viral load (≥10,000 copies/mL): 69% posoleucel vs 25% placebo achieved ≥1-log reduction; 75% for biweekly dosing.
Posoleucel well tolerated with balanced safety; no GVHD, cytokine release syndrome, or treatment-related acute rejection.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kalaris Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 15, 2023, AlloVir, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-039772

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.